Industry

DUBLIN–(BUSINESS WIRE)–The “Intranasal Drug & Vaccine Delivery Market Research Report by Distribution Channel, Application, Product, Dosage, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Intranasal Drug & Vaccine Delivery Market size was estimated at USD 44.85 billion in 2021, USD 48.21 billion in … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The pipeline guide provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action, route of … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “ATP Assays Market by Product (Consumables (Kits, Reagent, Microplate), Instrument (Luminometer, Spectrophotometers)), Application (Contamination, Disease Testing, Drug Discovery), End User (Hospitals, Pharmaceuticals, Food Testing) – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The global ATP assays market is projected to reach USD 412 million by 2027 from USD 276 … [Read more…]

LifeWorks Mental Health Index™ reveals 46 per cent of Canadians are feeling an increased sensitivity to stress TORONTO–(BUSINESS WIRE)–LifeWorks, a leading provider of digital and in-person total wellbeing solutions, today released its monthly Mental Health Index™ that showed the 46 per cent of Canadians feeling more sensitive to stress have a mental health score nearly … [Read more…]

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey OXFORD, England–(BUSINESS WIRE)–Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the … [Read more…]

Study is first of its kind to explore the impact of LHON on patients and their relatives in four different countries Study determined that the impact of LHON extends beyond vision-related activity limitations PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies … [Read more…]

On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, protocol submission planned in Q1 2023 … [Read more…]

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: H.C. Wainwright Global Investment Conference Fireside chat on May 24, 2022 starting at 8:30 a.m. ET Jefferies Healthcare Conference Presentation on June 9, 2022 from 9:00-9:30 a.m. ET Visit the Investors and Media section … [Read more…]

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that it has been named to 3BL Media’s 100 Best Corporate Citizens ranking for the second year in a row for environmental, social and governance (ESG) transparency and performance. 3BL … [Read more…]

On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, protocol submission planned in Q1 2023 … [Read more…]